NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.20
  • Forecasted Upside: -10.28 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.38 (-1.94%)
1 month | 3 months | 12 months
Get New Vanda Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VNDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VNDA

Average Price Target: $17.20
▼ -10.28% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Vanda Pharmaceuticals in the last 3 months. The average price target is $17.20, with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a -10.28% upside from the last price of $19.17.


The current consensus among 4 polled investment analysts is to buy stock in Vanda Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Bank of AmericaInitiated CoverageBuy$22.00Low
2/11/2021CitigroupBoost Price Target$14.00 ➝ $18.00Low
1/14/2021Smith Barney CitigroupDowngradeBuy ➝ NeutralMedium
1/14/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$14.00Medium
12/3/2020Jefferies Financial GroupBoost Price Target$16.00 ➝ $18.00High
10/29/2020Smith Barney CitigroupUpgradeNeutral ➝ BuyHigh
10/29/2020UBS GroupUpgradeNeutral ➝ Buy$14.00High
10/29/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ Buy$14.00High
6/9/2020CitigroupDowngradeBuy ➝ Neutral$14.00High
5/6/2020Stifel NicolausReiterated RatingHold$13.00High
3/16/2020OppenheimerDowngradeMarket Perform ➝ UnderperformHigh
3/15/2020Stifel NicolausReiterated RatingHold$13.00High
3/12/2020CitigroupUpgradeNeutral ➝ Buy$14.00High
2/27/2020OppenheimerLower Price Target$18.00 ➝ $12.00High
2/26/2020Stifel NicolausLower Price TargetHold$17.00 ➝ $13.00High
2/26/2020JMP SecuritiesReiterated RatingOutperform$52.00 ➝ $25.00High
2/2/2020Stifel NicolausReiterated RatingHoldHigh
11/7/2019CitigroupDowngradeBuy ➝ Neutral$19.00Low
11/7/2019Stifel NicolausReiterated RatingHold$17.00High
8/1/2019CitigroupUpgradeNeutral ➝ Buy$19.00High
7/31/2019Stifel NicolausReiterated RatingHold$17.00High
7/24/2019Stifel NicolausDowngradeBuy ➝ Hold$26.00 ➝ $17.00High
5/5/2019OppenheimerSet Price TargetHold$18.00High
5/2/2019CitigroupDowngradeBuy ➝ NeutralHigh
2/14/2019OppenheimerLower Price Target$29.00 ➝ $21.00High
2/14/2019Stifel NicolausReiterated RatingBuy$40.00Low
2/14/2019Cantor FitzgeraldReiterated RatingHold ➝ Reduce$26.00High
2/6/2019Stifel NicolausReiterated RatingBuyHigh
2/6/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$38.00 ➝ $30.00High
12/17/2018Cantor FitzgeraldSet Price TargetBuy$43.00Medium
12/11/2018CIBCReiterated RatingOutperform ➝ Market PerformLow
12/11/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$36.00 ➝ $44.00Low
12/11/2018OppenheimerDowngradeOutperform ➝ Hold$29.00Medium
12/11/2018UBS GroupDowngradeOutperform ➝ Market PerformMedium
12/10/2018Cantor FitzgeraldSet Price TargetBuy$43.00Low
12/7/2018CitigroupBoost Price TargetBuy ➝ Buy$31.00 ➝ $47.00Medium
12/6/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$36.00 ➝ $52.00Low
12/4/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$30.00 ➝ $40.00High
12/4/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$43.00High
12/3/2018OppenheimerReiterated RatingBuyHigh
12/3/2018Stifel NicolausSet Price TargetBuy$36.00High
11/15/2018Jefferies Financial GroupSet Price TargetBuy$30.00Low
11/8/2018Stifel NicolausSet Price TargetBuy$31.00Low
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$26.00High
11/8/2018OppenheimerSet Price TargetBuy$29.00N/A
10/31/2018Stifel NicolausReiterated RatingBuyLow
10/16/2018CitigroupBoost Price TargetBuy ➝ Buy$27.00 ➝ $31.00High
10/3/2018OppenheimerSet Price TargetBuy$29.00Low
10/3/2018Cantor FitzgeraldReiterated RatingHold$26.00Low
9/21/2018CIBCReiterated RatingOutperform ➝ OutperformLow
9/20/2018OppenheimerInitiated CoverageOutperform ➝ Buy$27.00 ➝ $29.00Low
9/13/2018Stifel NicolausInitiated CoverageBuy$30.00High
8/22/2018Cantor FitzgeraldInitiated CoverageNeutral$26.00High
8/2/2018OppenheimerSet Price TargetBuy$27.00Medium
8/2/2018Seaport Global SecuritiesReiterated RatingBuy$26.00Medium
5/23/2018CitigroupInitiated CoverageBuy$26.00Medium
5/3/2018OppenheimerSet Price TargetBuy$27.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/5/2018OppenheimerSet Price TargetBuy$27.00Low
2/28/2018Seaport Global SecuritiesReiterated RatingBuy$21.00Low
2/15/2018OppenheimerSet Price TargetBuy$27.00High
2/13/2018Jefferies Financial GroupReiterated RatingBuy$20.00Low
1/19/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$20.00Medium
1/8/2018OppenheimerReiterated RatingBuyHigh
11/12/2017OppenheimerReiterated RatingBuy$25.00N/A
10/29/2017OppenheimerSet Price TargetBuy$21.00 ➝ $26.00N/A
10/19/2017Piper Jaffray CompaniesSet Price TargetBuy$26.00N/A
9/14/2017OppenheimerReiterated RatingBuy$21.00High
9/14/2017Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $26.00High
8/29/2017Jefferies Financial GroupReiterated RatingBuy$21.00High
8/3/2017Piper Jaffray CompaniesSet Price TargetBuy$23.00High
8/3/2017HC WainwrightSet Price TargetBuy$18.00High
8/3/2017OppenheimerSet Price TargetBuy$21.00High
6/27/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$23.00Low
5/26/2017HC WainwrightInitiated CoverageBuy ➝ Buy$18.00Low
5/25/2017Jefferies Financial GroupReiterated RatingBuy$21.00Medium
4/12/2017Jefferies Financial GroupReiterated RatingBuy$21.00Low
4/12/2017CIBCReiterated RatingOutperform ➝ Outperform$21.00Low
4/12/2017OppenheimerInitiated CoverageOutperform$21.00Low
2/2/2017Jefferies Financial GroupSet Price TargetBuy$21.00N/A
1/8/2017Jefferies Financial GroupReiterated RatingBuy$23.00N/A
11/9/2016AegisInitiated CoverageBuy$24.00N/A
10/24/2016Piper Jaffray CompaniesSet Price TargetBuy$19.00N/A
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/A
10/6/2016Jefferies Financial GroupInitiated CoverageBuy$15.00 ➝ $23.00N/A
10/1/2016Piper Jaffray CompaniesSet Price TargetBuy$19.00N/A
8/29/2016Brean CapitalReiterated RatingBuy$20.00 ➝ $24.00N/A
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 ➝ $22.00N/A
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$16.00N/A
7/28/2016Brean CapitalSet Price TargetBuy$20.00N/A
7/28/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00N/A
(Data available from 6/18/2016 forward)
Vanda Pharmaceuticals logo
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More

Today's Range

Now: $19.17
Low: $19.17
High: $19.76

50 Day Range

MA: $17.73
Low: $15.92
High: $19.55

52 Week Range

Now: $19.17
Low: $9.00
High: $20.51


837,713 shs

Average Volume

482,723 shs

Market Capitalization

$1.07 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Vanda Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Vanda Pharmaceuticals in the last year: Bank of America Co., Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., Smith Barney Citigroup, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for VNDA.

What is the current price target for Vanda Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Vanda Pharmaceuticals in the last year. Their average twelve-month price target is $17.20, suggesting a possible downside of 10.3%. Bank of America Co. has the highest price target set, predicting VNDA will reach $22.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $14.00 for Vanda Pharmaceuticals in the next year.
View the latest price targets for VNDA.

What is the current consensus analyst rating for Vanda Pharmaceuticals?

Vanda Pharmaceuticals currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VNDA will outperform the market and that investors should add to their positions of Vanda Pharmaceuticals.
View the latest ratings for VNDA.

What other companies compete with Vanda Pharmaceuticals?

How do I contact Vanda Pharmaceuticals' investor relations team?

Vanda Pharmaceuticals' physical mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company's listed phone number is 202-734-3400 and its investor relations email address is [email protected] The official website for Vanda Pharmaceuticals is